Formulary Search Results for: CALCIUM AND VITAMIN D
5.3.3 Viral hepatitis - View Category
Restrictions:
Restricted to initiation by, or on the advice of, a specialist treating hepatitis B in accordance with local protocol.
Prescribing Notes:
Tenofovir for the treatment of hepatitis B is subject to an agreed Shared Care Protocol which allows the ongoing prescribing to be carried out by the patient's GP under guidance and review by the acute specialist.
To access this Shared Care Agreement, and others, click here
2.8.1 Parenteral anticoagulants - View Category
Restrictions:
Restricted to specialist initiation only. The treatment and prevention of VTE in patients with solid tumours use is restricted to initiation by healthcare professionals experienced in the treatment of VTE and use according to local protocol.
Prescribing Notes:
When dalteparin is used in the extended treatment of VTE and prevention of recurrence in patients with solid tumours, prescribers are reminded that a dose reduction is required following the first month of treatment, and where there is a transfer of care, the need for this dose reduction should be communicated clearly. For further dosing information, see the product literature or BNF.
4.2.2 Antipsychotic depot injections - View Category
Restrictions:
Restricted to specialist initiation only.
Prescribing Notes:
For further information, see the NHSGGC depot (LAI) algorithm.
4.2.2 Antipsychotic depot injections - View Category
Restrictions:
Restricted to specialist initiation only.
Prescribing Notes:
For further information, see the NHSGGC depot (LAI) algorithm.
4.2.2 Antipsychotic depot injections - View Category
Restrictions:
Restricted to specialist initiation only.
Prescribing Notes:
For further information, see the NHSGGC depot (LAI) algorithm.
4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder - View Category
Restrictions:
Restricted to second line therapy for the treatment of ADHD and initiation by child or adolescent psychiatrists or paediatricians with expertise in ADHD.
8.1.2 Anthracyclines and other cytotoxic antibiotics - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following:
- AML: The treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (AML) or AML with myelodysplasia related changes.
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following indications:
- Unresectable or metastatic BRAF V600 mutation-positive metastatic melanoma who have received no prior therapy.
- In combination with trametinib for the adjuvant treatment of adults with stage III melanoma with a BRAF V600 mutation following complete resection.
- In combination with trametinib for the treatment of adults with locally advanced or metastatic anaplastic thyroid cancer with evidence of a BRAF V600E mutation and with no satisfactory locoregional treatment options (as approved by NCMAG).
Prescribing Notes:
The following indications are not recommended for use by the SMC and are non-Formulary:
- In combination with trametinib for the treatment of adults with advanced non-small cell lung cancer with BRAF V600 mutation.
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations, is restricted to specialist use only in accordance with regional protocol [NHS network access required].
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following indications:
Multiple Myeloma:
- Use as monotherapy for the treatment of adults with relapsed and refractory multiple myeloma is restricted to use as a fourth-line treatment option.
- In combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one prior therapy only.
- Use in combination with bortezomib, thalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
- In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Amyloidosis:
- Use in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly-diagnosed systemic light chain (AL) amyloidosis.
Prescribing Notes:
The following indications for the infusion preparation are not recommended by SMC and are non-Formulary:
Multiple Myeloma:
- In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
- Combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.